Advertisement

Topics

Companies Related to "Acne Treatments Promote Antibiotic Resistance" [Most Relevant Company Matches] RSS

15:41 EDT 25th June 2018 | BioPortfolio

Here are the most relevant search results for "Acne Treatments Promote Antibiotic Resistance" found in our extensive corporate database of over 50,000 company records.

Showing "Acne Treatments Promote Antibiotic Resistance" Companies 1–25 of 1,500+

Extremely Relevant

Pharmaceutica Limited

Pharmaceutica Limited is a privately owned pharmaceutical company founded in March 2003, to discover and develop a new generation of anti-infective drug technologies that combat the increasing problem caused by the rapid evolution of resistance by pathogenic organisms. The company is targeting both human and veterinary applications for its technologies.The initial focus is to find a solution to th...


Relevant

Allecra Therapeutics GmbH

Allecra Therapeutics Allecra is a biopharmaceutical company established in 2013 focussed on the development of novel treatments to combat multi drug-resistant bacterial infections. Allecra’s Mission Allecra’s mission is to contribute towards the global effort to combat antibiotic resistance by developing new treatments which overcome emerging resistance mechanisms thereby saving ...

Ipsat Therapies Oy

Ipsat Therapies Ltd is a Finnish biotechnology company developing its proprietary IPSAT™ (“Intestinal Protection System in Antibiotic Treatment”) family of products for the prevention of hospital infections and antibiotic resistance


Proactiv

Proactiv® Solution, the world's best selling acne system, is a leader in acne prevention and treatment formulated to offer consumers the opportunity for a lifetime of smooth, clear, healthy-looking skin. Now with new micro-crystal benzoyl peroxide, Proactiv utilizes Combination Therapy® to directly target the root causes of acne – bacteria, oil ...

Arsanis Inc

Arsanis is committed to the development of monoclonal antibody therapeutics against severe infectious diseases that cannot be controlled with currently available medical treatments. The company’s major focus is on life threatening infections that are caused by antibiotic resistant pathogens, occur in immune compromised patients or are associated with ...

Arsanis, Inc

Arsanis is committed to the development of monoclonal antibody therapeutics against severe infectious diseases that cannot be controlled with currently available medical treatments. The Company’s major focus is on life threatening infections that: are caused by antibiotic resistant pathogens; occur in immune compromised patients; or are associated wit...

Arsanis Biosciences GmbH

Arsanis is committed to the development of monoclonal antibody therapeutics against severe infectious diseases that cannot be controlled with currently available medical treatments. The Company’s major focus is on life threatening infections that are caused by antibiotic resistant pathogens, occur in immune compromised patients or are associated with ...

Arsanis, Inc.

Arsanis is committed to the development of monoclonal antibody therapeutics against severe infectious diseases that cannot be controlled with currently available medical treatments. The Company’s major focus is on life threatening infections that: are caused by antibiotic resistant pathogens; occur in immune compromised patients; or are associated wit...

Paratek Pharmaceuticals Incorporated

Paratek's mission is to overcome the major worldwide problem of bacterial resistance through the application of new proprietary technology and through the development of new antibiotics. Paratek has established two product development programs to identify and develop new pharmaceuticals for the treatment of infectious diseases:The Tetracycline Resistance Project ("Tet Project") based on expertise ...

Phage Biotech Ltd.

Phage-Biotech Ltd. was incorporated in March 2000, as a new player in the emerging field of Phage Therapy. The Company’s mission is to develop proprietary Phage-based anti-infective therapeutics to combat the increasing number of antibiotic-resistant infections worldwide. The Company has two short-term strategic objectives:To identify and formulate proprietary topical Phage preparations from dis...

MaxClarity

The MaxClarity Acne Treatment System provides consumers with an acne solution that is easy to use, effective and backed by science from dermatology experts. The MaxClarity System uses VersaFoam technology, which allows two proven acne fighting ingredients, benzoyl peroxide and salicylic acid, to penetrate the skin quickly and fight acne at the source before it becomes a pimple. The system includes...

AdvanDx, Inc

AdvanDx announces that at the recent American Society for Microbiology (ASM) meeting in Orlando, Florida, EVIGENE™ kits for detecting specific antibiotic resistance, virulence, and toxicity markers such as methicillin-resistance, vancomycin-resistance, PVL and TSST-1 in Staphylococcus aureus and enterococci, were launched for research use only in the United States. EVIGENE was officially launch...

Paratek Pharmaceuticals

Paratek Pharmaceuticals, Inc. is engaged in the discovery and commercialization of new therapeutics that treat serious and life-threatening diseases, with a particular focus on the growing worldwide problem of antibiotic resistance. Paratek is advancing novel compounds that can circumvent or block bacterial resistance involving technology initially developed by Paratek co-founder Dr. Stuart Levy's...

Jeffrey Klein M.D. Dermatology & Associates

Jeffrey Klein M.D. Dermatology & Associates serves patients throughout South Orange County, California with comprehensive cosmetic dermatology and general dermatology treatments, including medical skin conditions that range from acne and eczema, to Mohs surgery for skin cancer. Complete medical spa services include Botox cosmetic, laser skin resurfacing, c...

Mpex Pharmaceuticals, Inc.

Mpex Pharmaceuticals is a clinical stage biopharmaceutical company whose mission is to develop important new therapies to combat the growing issue of antibiotic resistance. The company's internal development pipeline focuses on combining proprietary formulations, PK/PD strategies and novel potentiating agents with proven antibiotics to overcome or directly inhibit the molecular mechanisms in bacte...

Mpex Pharmaceuticals

Mpex Pharmaceuticals is focused on the discovery and development of new anti-bacterial drugs that meet the growing clinical need created by multi-drug resistant bacterial pathogens. It is well documented that antibiotic resistance is a growing, serious problem in both the hospital and community setting. Mpex's approach is to improve the activity of existing antibiotics by utilizing methods and pot...

Premiere Dermatology and Laser Center

After more than 20 years of treating patients who sought better skin and hair care products, Dr. Cobos developed RC Dermatology skin care, a medical grade product line that combines maximum treatment results with effective luxury. RC Dermatology includes RC freshSKIN for acne and oily skin, and RC freshHair, with RC Complex Acne/Oil Control Formula(TM) which treats and prevents acne, acne rosacea,...

AB BIODISK

The AB BIODISK name, company spirit and reputation are based on commitment to the highest standards of science. The company is perhaps best known for its dedication to antimicrobial resistance testing since the early 1950s. The mission left by its scientific founder, Hans Ericsson, Professor of Microbiology at the Karolinska Institute, “to Promote the Rational Use of Antibiotics” has been fait...

Tetraphase Pharmaceuticals

Tetraphase Pharmaceuticals is a clinical-stage life science company with a groundbreaking synthetic chemistry technology platform that has the power to deliver solutions to the global health crisis caused by antibiotic resistance. Since the company’s inception in 2006, Tetraphase has developed a robust antibiotic franchise that offers the potential to ...

Microbiotix, Inc.

Microbiotix, Inc. is a privately held, product-focused biopharmaceutical company engaged in the research and development of novel small molecule, anti-infective drugs that address commercially significant medical markets. The company currently has four novel compound series in research and development. Microbiotix currently has in development MBX 500, the first antibiotic that targets the DNA po...

Discuva

Discuva aims to revolutionise the treatment of disease caused by bacterial infection by discovering and developing new antibiotics against highly drug-resistant pathogens. The company’s innovative proprietary technologies both identify new small molecule drugs against novel bacterial targets and facilitate their progression through to drug candidates ...

PolyMedix, Inc.

PolyMedix is a publicly traded biotechnology company focused on the development of novel drugs and biomaterials for the treatment of serious acute cardiovascular disorders and infectious diseases. PolyMedix uses a rational drug design approach to create non-peptide small molecule drug candidates and polymers that mimic the activity of proteins. PMX-60056, ...

MethylGene Incorporated

MethylGene is engaged in the discovery and development of drugs for diseases for which there are currently limited or no treatments. Research on the Company's first target, the DNA Methyltransferase enzyme, has yielded a unique anti-cancer drug presently in Phase I clinical trials. Several other targets are being investigated, including HDAC (histone deacetylase) and ER-1 (early response gene) for...

UTILITY therapeutics Ltd

UTILITY is focused on developing and commercialising antibiotics in the US, to address the significant threat faced by healthcare systems and patients from multi-drug resistant bacterial infections. The World Health Organisation has stated that antibiotic resistance is one of the biggest threats to global health, food security, and development today.

VenatoRx Pharmaceuticals, Inc.

VenatoRx Pharmaceuticals is a private pharmaceutical company dedicated to the discovery and development of novel agents to address the threat of antibiotic bacteria resistance. Its lead clinical program combines VNRX-5133, a novel β-lactamase inhibitor, with an approved and marketed β-lactam antibiotic. This press release contains “forward-looking ...


More From BioPortfolio on "Acne Treatments Promote Antibiotic Resistance"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks